| BSI-201 |
| 4-iodo-3-nitrobenzamide |
| (CAS 160003-66-7) |
 |
| Description： |
Iniparib (previously BSI 201) (4-iodo-3-nitrobenzamide) was a drug candidate for cancer treatment. It was originally believed to act as an irreversible inhibitor of PARP1 (hence, a PARP inhibitor) and possibly other enzymes through covalent modification,[1][2] but its effects against PARP were later disproven.[3][4] It underwent clinical trials for treatment of some types of breast cancer,[5][6] but was discontinued after disappointing Phase III clinical trials.
|
| Product No. |
KT00228 |
| Product Name |
BSI-201 |
| Synonyms |
Iniparib |
| Formal Name |
4-iodo-3-nitrobenzamide |
| CAS Number |
160003-66-7 |
| Molecular Formula |
C7H5IN2O3 |
| Formula Weight |
292.03 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500 |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
A-966492
AG14361
AZD-2461
BMN-673
BMN-673 8R,9S
G007-LK
GW 501516
INO-1001
JW 55
MK-4827
|
|
